List of Excipients in Branded Drug INFLIXIMAB

« Back to Dashboard

Infliximab Excipient Strategy and Commercial Opportunities

Last updated: August 30, 2026

Infliximab is a mature anti-TNF biologic with extensive biosimilar competition and limited remaining value in the core molecule. Commercial opportunity has shifted to formulation differentiation, subcutaneous delivery, improved stability, manufacturing efficiency, interchangeability support, and market-specific presentations. The leading excipient platform remains a low-concentration, lyophilized intravenous formulation based on sucrose, polysorbate 80, and phosphate buffer. Higher-value opportunities involve ready-to-use liquid products, concentrated subcutaneous formulations, lower surfactant burden, improved aggregation control, and presentations that reduce hospital preparation time.

What excipients are used in infliximab products?

Approved infliximab products generally use a small excipient system designed to preserve antibody structure during freeze-drying, reconstitution, storage, and intravenous infusion.

Product	Active ingredient	Route	Principal excipients or formulation components	FDA status
Remicade	Infliximab	Intravenous infusion	Sucrose, polysorbate 80, sodium phosphate buffer	Reference product
Inflectra	Infliximab-dyyb	Intravenous infusion	Sucrose, polysorbate 80, phosphate buffer	Biosimilar
Renflexis	Infliximab-abda	Intravenous infusion	Sucrose, polysorbate 80, sodium phosphate buffer	Biosimilar
Ixifi	Infliximab-qbtx	Intravenous infusion	Sucrose, polysorbate 80, phosphate buffer	FDA-approved biosimilar; commercial availability has been limited
Avsola	Infliximab-axxq	Intravenous infusion	Sucrose, polysorbate 80, sodium phosphate buffer	Biosimilar

The products are supplied as sterile, preservative-free lyophilized powders. Reconstitution and dilution are required before infusion. The labels typically identify sucrose as a stabilizing sugar, polysorbate 80 as a surfactant, and sodium phosphate as a buffering system. Product-specific concentrations and quantitative excipient disclosures should be verified against the current prescribing information.[1-5]

Why is sucrose used in infliximab formulations?

Sucrose protects the antibody during lyophilization and storage by replacing some of the hydrogen-bonding interactions lost during drying. It also helps form a stable amorphous matrix around the protein. The commercial benefits are established manufacturing robustness and a long regulatory history.

Sucrose does not provide the same reconstitution or tonicity profile as every alternative sugar. Trehalose, mannitol, sorbitol, and combinations of sugars and polyols may support different cake structures, reconstitution times, and aggregation profiles. Replacing sucrose can therefore create a formulation differentiation opportunity, but the change requires extensive comparability work.

What is the role of polysorbate 80?

Polysorbate 80 reduces adsorption of infliximab to glass, plastic, tubing, and infusion equipment. It also limits agitation-induced interfacial stress. The main liabilities are oxidative degradation, hydrolysis, formation of subvisible particles, and potential interaction with the protein or container system.

A commercial formulation strategy may evaluate polysorbate 20, poloxamers, or low-surfactant systems. The substitution is technically difficult because surfactant changes can affect:

• High-molecular-weight aggregate formation
• Subvisible particle generation
• Protein adsorption
• Oxidation and peroxide exposure
• Container closure compatibility
• Infusion-line performance
• Storage stability after reconstitution

A low-polysorbate product may have a meaningful value proposition if it maintains stability while reducing particle burden and improving compatibility with prefilled or ready-to-use presentations.

What formulation characteristics matter most for infliximab commercialization?

The most commercially relevant attributes are not simply chemical stability. They are operational attributes that reduce infusion-center labor, waste, and treatment time.

Attribute	Commercial effect	Excipient relevance
Long refrigerated shelf life	Reduces inventory loss	Buffer, sugar, surfactant, container interaction
Short reconstitution time	Reduces pharmacy labor	Cake structure, cake porosity, protein concentration
Low foaming	Improves preparation consistency	Surfactant level and mixing process
Low particle load	Supports quality and infusion handling	Surfactant purity, oxidation control, agitation resistance
Extended in-use stability	Enables scheduling flexibility	Buffer capacity, antimicrobial strategy, container closure
High concentration	Supports subcutaneous delivery	Viscosity control, protein-protein interaction, surfactant selection
Low viscosity	Enables autoinjector or syringe use	Amino acids, salts, pH, protein concentration
Reduced infusion volume	Lowers chair time	Concentration, osmolality, viscosity
Consistent reconstitution	Reduces dosing errors	Lyophilization cycle and excipient matrix

Because infliximab is administered repeatedly for chronic immune-mediated diseases, small workflow improvements can have material value for hospitals and specialty providers.

What excipient strategies can differentiate an infliximab biosimilar?

Ready-to-use liquid infliximab

A liquid formulation would remove reconstitution and reduce preparation steps. The technical problem is that liquid products expose the antibody to longer periods of aqueous degradation, including aggregation, fragmentation, oxidation, deamidation, adsorption, and particle formation.

A liquid infliximab product may use:

• Histidine or phosphate buffering
• Sucrose, trehalose, or another stabilizing sugar
• Polysorbate 20 or polysorbate 80
• Arginine or other amino acids to control aggregation
• Methionine or another oxidation-control excipient
• Chelating agents where justified by degradation pathways
• Low-binding container and closure systems

The highest-value liquid product would combine refrigerated stability, low particle formation, acceptable viscosity, and a commercially practical shelf life. A liquid formulation may also reduce pharmacy manipulation and make home or outpatient administration more feasible.

High-concentration subcutaneous formulation

Intravenous infliximab requires an infusion setting. A concentrated subcutaneous formulation could move treatment toward self-administration, office injection, or shorter healthcare encounters. The formulation must address viscosity, injection force, dose volume, immunogenicity, and device compatibility.

High-concentration strategies commonly evaluate:

• Arginine to reduce protein-protein interactions
• Histidine or acetate buffers
• Trehalose or sucrose for conformational stabilization
• Polysorbate 20 or 80 at low concentration
• Amino acids that reduce self-association
• pH optimization to balance stability and viscosity

The commercial opportunity is strongest where the product can support a practical injection volume without creating unacceptable pain, high injection force, or device failure.

European development of subcutaneous infliximab, including CT-P13 SC, demonstrates that the product class can support a differentiated route strategy. The regulatory pathway and approval status differ by jurisdiction, and the U.S. market requires separate FDA review.[6]

Alternative surfactant systems

Polysorbate degradation can generate fatty-acid particles and increase product variability. A biosimilar developer may seek a lower-risk surfactant system based on:

• Polysorbate 20
• Poloxamer 188
• Mixed surfactants
• Reduced surfactant concentration
• Improved surfactant raw-material controls

The commercial advantage depends on whether the alternative improves real-world stability without creating a new comparability burden. A formulation patent covering a specific surfactant concentration, buffer range, or liquid stability profile may be more valuable than a broad excipient substitution that is difficult to distinguish clinically.

What formulation patents protect infliximab products?

Infliximab’s foundational molecule and original anti-TNF patent position are mature. The strongest current intellectual-property opportunities generally relate to product configuration rather than the antibody sequence itself.

Relevant claim categories include:

1. Liquid antibody formulations with defined pH and excipient concentrations.
2. High-concentration infliximab compositions.
3. Subcutaneous delivery systems.
4. Specific surfactant and sugar combinations.
5. Low-aggregate or low-particle formulations.
6. Container closure systems and prefilled devices.
7. Reconstitution and dilution methods.
8. Stable formulations with defined storage periods.
9. Manufacturing processes that control oxidation, deamidation, or aggregation.
10. Method-of-use claims tied to dosing, induction, maintenance, or patient subgroups.

Patent value depends on claim scope, priority date, jurisdiction, prosecution history, terminal disclaimers, written-description support, and freedom-to-operate analysis. A formulation patent may have commercial relevance even when the basic biologic patent has expired, but it must cover a product characteristic that competitors cannot easily design around.

Are infliximab formulation patents listed in the Orange Book?

No. Biologics such as infliximab are not generally listed in the FDA Orange Book. The relevant FDA reference-product and biosimilar information appears in the Purple Book. Patent certification mechanics also differ from small-molecule Hatch-Waxman litigation.

Biosimilar applicants submit a biosimilar application under section 351(k) of the Public Health Service Act. Patent disputes are handled through the BPCIA patent-exchange framework and related litigation, rather than through standard Orange Book Paragraph IV certification.[7]

When did infliximab lose regulatory exclusivity?

Remicade received FDA approval in 1998. The BPCIA created 12 years of reference-product exclusivity for qualifying biologics. For Remicade, that period expired before the FDA approved the first U.S. infliximab biosimilar.

Event	Date
Remicade U.S. approval	Aug. 24, 1998
First U.S. infliximab biosimilar approval, Inflectra	April 5, 2016
First U.S. biosimilar commercial launch	Oct. 2016
Approximate end of 12-year reference-product exclusivity	2010
Renflexis approval	May 2017
Ixifi approval	Dec. 2017
Avsola approval	Dec. 2019

Regulatory exclusivity has therefore expired. The commercial barriers now arise from manufacturing scale, physician adoption, payer contracts, interchangeability status, supply reliability, immunogenicity data, and product-specific patents.

Which companies are challenging Remicade commercially?

The principal U.S. competitors have been Celltrion, Samsung Bioepis, Pfizer, and Amgen.

Company or product	Biosimilar designation	Strategic position
Celltrion, Inflectra	Infliximab-dyyb	Early U.S. entrant; broad global presence
Samsung Bioepis, Renflexis	Infliximab-abda	U.S. biosimilar competitor with hospital and payer relevance
Pfizer, Ixifi	Infliximab-qbtx	Approved product with limited visible U.S. commercial impact
Amgen, Avsola	Infliximab-axxq	Later entrant with major U.S. biologics infrastructure
Celltrion, Remsima SC	Subcutaneous infliximab	Route-of-administration differentiation in selected markets

Competition is no longer based only on wholesale acquisition price. Hospital systems evaluate acquisition cost, reimbursement spread, contracting, infusion-center logistics, inventory, and switching policy. Payers evaluate net price, formulary leverage, and interchangeability.

What is the biosimilar and interchangeability risk for infliximab?

Infliximab has high biosimilar exposure because the reference product is administered in controlled healthcare settings and because multiple biosimilars have substantial clinical experience.

The main competitive risks are:

• Price erosion from multiple suppliers
• Payer-mandated switching
• Hospital formulary conversion
• Contracting tied to broader immunology portfolios
• Reduced physician resistance after long-term biosimilar use
• Cross-border reference pricing
• Future subcutaneous products that change site-of-care economics

The FDA has designated some infliximab biosimilars as interchangeable. Interchangeability is relevant to pharmacy-level substitution under state law, although many infliximab doses are administered in infusion centers rather than dispensed through retail pharmacies. The practical commercial benefit may therefore be smaller than for self-administered biologics, but it can still support payer and health-system adoption.[7]

What FDA regulatory issues affect an excipient-differentiated infliximab product?

A biosimilar with a materially different formulation must demonstrate that the change does not undermine biosimilarity. FDA review will focus on analytical similarity, product-related impurities, stability, immunogenicity, pharmacokinetics, and clinical relevance.

Key regulatory issues include:

Excipients and immunogenicity

Changes in surfactants, buffers, sugars, or amino acids can affect aggregation and particles. Those attributes can influence anti-drug antibody formation. The applicant must connect formulation differences to a defensible analytical and clinical risk assessment.

Route of administration

A subcutaneous product is not a simple formulation change from an intravenous biosimilar. It may require a distinct clinical development plan, pharmacokinetic assessment, local tolerability data, device studies, and route-specific labeling.

Interchangeability

A differentiated formulation may be biosimilar without being interchangeable. The applicant must evaluate the applicable FDA standard and switching evidence requirements.

Device combination products

Prefilled syringes, autoinjectors, and wearable injectors add extractables and leachables, container closure, human factors, dose accuracy, and device reliability requirements.

How strong is the infliximab patent estate?

The core composition-of-matter position is weak from a commercialization perspective because infliximab has been available for decades and U.S. regulatory exclusivity has expired. The remaining patent strength is product-specific.

Patent category	Relative strength	Commercial significance
Original anti-TNF antibody claims	Low to moderate	Generally mature or expired in major markets
Lyophilized IV formulation claims	Low to moderate	May affect narrow product configurations
Liquid formulation claims	Moderate to high if technically narrow and unexpired	Can protect ready-to-use products
High-concentration SC formulation claims	Moderate to high	Supports route and device differentiation
Manufacturing-process claims	Moderate	Can create supply and scale barriers
Method-of-use claims	Variable	Depends on enforceability and prescribing overlap
Device and container claims	Moderate	Relevant to prefilled and self-administration products

The strongest practical moat is often the combination of formulation, device, manufacturing process, regulatory data, and commercial contracting. A single narrow excipient patent rarely prevents all competing infliximab products.

What commercial opportunities exist for infliximab excipients?

Hospital efficiency

A formulation that reduces reconstitution time, infusion volume, or product waste can support hospital adoption even without a large clinical difference. Pharmacy labor and chair utilization are measurable economic outcomes.

Subcutaneous conversion

Subcutaneous infliximab can capture value from site-of-care migration. The opportunity is greatest in maintenance therapy, where patients have predictable dosing and may prefer reduced clinic visits.

Pediatric and low-dose presentations

Smaller vial sizes, improved dose flexibility, and reduced wastage can address pediatric and low-body-weight populations. The excipient system must remain stable across different fill volumes and reconstitution conditions.

Emerging-market products

Markets with limited cold-chain capacity may favor longer shelf life, more robust shipping stability, smaller package sizes, and simplified preparation. Geographic patent and regulatory analysis is essential because a formulation may be commercially open in one jurisdiction and restricted in another.

Contract manufacturing and platform licensing

Companies with antibody stabilization platforms can license excipient systems, lyophilization cycles, analytical methods, or delivery devices to biosimilar developers. The most defensible licensing assets are platform technologies that apply to multiple antibodies, not a single infliximab formulation.

How does infliximab compare with other anti-TNF biologics?

Product	Administration	Excipient and commercial implication
Infliximab	IV; SC in selected markets	Strong opportunity for ready-to-use and SC conversion
Adalimumab	Primarily SC	Mature device and formulation competition; less infusion-center value
Golimumab	SC or IV depending product	Smaller competitive base; route-specific differentiation
Certolizumab pegol	SC	Pegylated fragment with different formulation constraints
Etanercept	SC	Established self-injection market and biosimilar competition

Infliximab has a larger infusion-center efficiency opportunity than self-administered anti-TNF products. Adalimumab has a more developed home-injection infrastructure, while infliximab offers greater potential value from reducing infusion dependence.

What generic launch risks exist for infliximab?

Traditional generic substitution is not the primary risk. The relevant competitors are biosimilars and differentiated biologics.

A new entrant faces:

• Analytical similarity requirements
• Cell-line and process comparability
• Low aggregate and particle specifications
• Clinical immunogenicity expectations
• Manufacturing scale-up risk
• Cold-chain and vial supply requirements
• Payer contracting pressure
• Physician and hospital switching barriers
• Potential formulation and device patents
• Price erosion from established biosimilars

A low-cost lyophilized intravenous product can enter a crowded market but may struggle to achieve durable margins. A differentiated liquid or subcutaneous product has greater upside but carries higher development and regulatory costs.

Key Takeaways

• Infliximab’s established excipient platform uses sucrose, polysorbate 80, and phosphate buffer in a preservative-free lyophilized intravenous product.
• The core molecule has limited remaining exclusivity value; formulation and delivery systems are the principal areas for differentiation.
• Liquid, ready-to-use, high-concentration, and subcutaneous formulations offer the clearest commercial opportunities.
• Surfactant selection, aggregation control, viscosity, particle generation, and container compatibility are central formulation issues.
• Infliximab biologics are tracked in the FDA Purple Book, not the Orange Book.
• Biosimilar competition is established in the United States, with Inflectra, Renflexis, Ixifi, and Avsola approved.
• The strongest commercial moat is a combined formulation, device, manufacturing, regulatory, and contracting position.
• Hospital labor reduction and site-of-care migration can create more value than a modest reduction in drug acquisition cost.

FAQs

Can infliximab be formulated without polysorbate 80?

Yes, but removing polysorbate 80 requires a replacement strategy that controls adsorption, agitation-induced aggregation, and particle formation. A polysorbate-free formulation may use another surfactant, a protein-stabilizing excipient system, or a redesigned container and process.

Is a liquid infliximab formulation commercially superior to a lyophilized product?

A liquid product can reduce reconstitution labor and preparation errors, but it faces higher aqueous stability and shipping requirements. Commercial superiority depends on shelf life, waste reduction, infusion-center workflow, and net pricing.

Can excipients improve infliximab immunogenicity?

Excipients can reduce aggregation and particles, which may lower one source of immunogenicity risk. They do not eliminate anti-drug antibody formation, which also depends on the antibody sequence, impurities, dose, disease state, and patient factors.

Does subcutaneous infliximab eliminate infusion-center competition?

It can reduce infusion-center use for maintenance therapy, but patients may still require loading doses, clinical monitoring, or administration by healthcare professionals. The commercial effect depends on label, reimbursement, device design, and patient preference.

Are infliximab formulation patents likely to block biosimilar entry?

Broad blocking risk is limited for a mature product, but narrow patents can affect specific liquid formulations, high-concentration products, devices, manufacturing processes, or subcutaneous presentations. Freedom-to-operate analysis must be performed by jurisdiction and product configuration.

References

1. U.S. Food and Drug Administration. (2024). Remicade (infliximab) prescribing information.
2. U.S. Food and Drug Administration. (2024). Inflectra (infliximab-dyyb) prescribing information.
3. U.S. Food and Drug Administration. (2024). Renflexis (infliximab-abda) prescribing information.
4. U.S. Food and Drug Administration. (2024). Ixifi (infliximab-qbtx) prescribing information.
5. U.S. Food and Drug Administration. (2024). Avsola (infliximab-axxq) prescribing information.
6. European Medicines Agency. (2024). Remsima and Remsima SC: European public assessment information.
7. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
8. U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products.
9. U.S. Food and Drug Administration. (1998). Approval history for Remicade (infliximab).